Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine in Patients With AML, MDS or CMML

NCT04730258 is registered in ClinicalTrials.gov with Treadwell Therapeutics, Inc as lead sponsor.

NCT NCT04730258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04730258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine in Patients With AML, MDS or CMML
Lead sponsor
Treadwell Therapeutics, Inc
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 16, 2021
Completion date
January 31, 2026
Enrollment
72 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, aml, chronic myelomonocytic leukemia, cmml, mds, myelodysplastic syndromes